Our lead program is dedicated to finding a solution to preeclampsia. This life-threatening condition can impact both the mother and child, and current treatment options are limited. By focusing our efforts on understanding and addressing this disease, we aim to provide new hope for affected families and improve overall maternal health.
In addition to preeclampsia, Aggamin is exploring a range of vascular diseases to develop treatments that improve quality of life and reduce healthcare burdens. Through rigorous research and collaboration with experts in the field, we strive to make meaningful progress toward more effective and accessible treatments for these conditions.
Preeclampsia is a life-threatening condition affecting 5% of pregnancies worldwide. Aggamin's research targets this condition to mitigate its impact on mothers and babies.
Research on preeclampsia is crucial to develop solutions that can save lives, improve pregnancy outcomes, and enhance maternal and infant health globally.
Aggamin utilizes cutting-edge science to develop innovative therapies that can effectively combat preeclampsia and improve the well-being of pregnant women and their babies.
Aggamin's innovative therapies aim to improve patient outcomes, transform healthcare systems, and address unmet needs in vascular health.